FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.

Alcon’s IFRS operating margin improved dramatically from 15.1% in Q1 2024 to 19.1% in Q1 2025. The following bridge chart explains the components of this improvement: ...

The company reported $1.4 billion in cash and cash equivalents on its balance sheet, with total debt of $4.7 billion. Capital expenditures totaled $106 million in the quarter, primarily for ...

Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).

Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Turkey Contact Lens Market by Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to ResearchAndMarkets.com's offering.

Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Turkey Contact Lens Market by Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to ResearchAndMarkets.com's offering. Turkey's ...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR ® (acoltremon ...

On Tuesday, BofA Securities analysts reduced the price target for Alcon (NYSE:ALC) Inc. stock to CHF89 from CHF96, while maintaining a Buy rating. The adjustment follows a challenging first ...